

## Contents of volume 22

No. 1 (pp 1-94) published June 30, 1988  
 No. 2 (pp 95-182) published August 8, 1988  
 No. 3 (pp 183-274) published September 2, 1988  
 No. 4 (pp 275-358) published October 3, 1988

- Abikhail F → Dubois J, et al. 282  
 Abramson I → Chan TCK, et al. 83  
 Agnelli G → Costantini V, et al. 289  
 Ahmed T → Mittelman A, et al. 63  
 Aigner KR → Link KH, et al. 58  
 Alberts DS → Dorr RT, et al. 299  
 Allegrucci M → Costantini V, et al. 289  
 Andersson M, Domellöf, Häggmark S, Johansson G, Reiz S, Gustavsson B: Cardiopulmonary hemodynamics and pharmacokinetics after hepatic intraarterial infusion of 5-fluorouracil (5-FU). An experimental study in the pig 251  
 Ardalán B → Singh G, et al. 191  
 Ardiet C → Pinkerton CR, et al. 271  
 Arlin Z → Mittelman A, et al. 63  
 Arnold P → Mittelman A, et al. 63  
 Asamura M → Kanamaru R, et al. 197  
 Ashikari R → Mittelman A, et al. 63  
 Atassi G → Dubois J, et al. 282  
 Au JL-S, Wientjes MG, Bramer SL: Effect of uridine coadministration on 5'-deoxy-5-fluorouridine disposition in rats 5  
 Baguley BC → Paxton JW, et al. 235  
 Barnard DL → Central Lymphoma Group, et al. 141  
 Behrens DL → Shen HL, et al. 183  
 Bekesi JG → Houghton PJ, et al. 201  
 Benard P → Laurent F, et al. 308  
 Berens MF → Higashihara J, et al. 215  
 Berkholder S → Gullia KS, et al. 211  
 Bertagna C → Pendyala L, et al. 69  
 Biron P → Pinkerton CR, et al. 271  
 Blackledge GRP → Central Lymphoma Group, et al. 141  
 Blair AH → Uadia PO, et al. 175  
 Blaise D → Gaspard MH, et al. 256  
 Bleiberg H, Gerard B, Dalesio O, Crespeigne N, Rozenweig M: Activity of a new antiemetic agent: alizapride. A randomized double-blind crossover controlled trial 316  
 Boccardo F, Decensi A, Guarneri D, Martorana G, Giberti C, Giuliani L: Estramustine phosphate (estracyt) following androgens in men with refractory stage D2 prostate cancer 172  
 Borsi DJ, Schuler D, Moe PJ: Methotrexate administered by 6-h and 24-h infusion: a pharmacokinetic comparison 33  
 Borsi JD, Klepp O, Moe PJ: PharmCalc: Program for the calculation of clinical pharmacokinetic parameters of methotrexate 339  
 Bradley C → Gouyette A, et al. 114  
 Bramer SL → Au JL-S, et al. 5  
 Brenner DE → Cusack BJ, et al. 294  
 Brodfuehrer JI, Wilke TJ, Powis G: Pharmacokinetics and metabolism of the antitumor agent sulfamic acid, 1,7-heptanediyl ester (sulfamic acid diester) in the mouse and beagle dog 120  
 Brunat-Mentigny M → Pinkerton CR, et al. 271  
 Buamah PK → Skillen AW, et al. 228  
 Calvert R → Pearcey R, et al. 353  
 Canal P → Laurent F, et al. 308  
 Canetta RM → Gaver RC, et al. 263  
 Cantwell BMJ → Skillen AW, et al. 228  
 Carcassonne Y → Gaspard MH, et al. 256  
 Carlsson J → Nederman T, et al. 21  
 Cassidy J → Gouyette A, et al. 114  
 Cavalli F → Zucchetti M, et al. 87  
 Central Lymphoma Group: Stuart NSA, Blackledge GRP, Child JA, Fletcher J, Perren TJ, O'Brien CJ, Jones EL, Ellis IO, Kavanagh JA, Kelly KA, MacLennan ICM, Cullen MH, Barnard DL, Simons AV: A new approach to the treatment of advanced high-grade non-Hodgkin's lymphoma: intensive two-phase chemotherapy 141  
 Chan TCK, Markman M, Pfeifle CE, Taetle R, Abramson I, Howell SB: Uridine pharmacokinetics in cancer patients 83  
 Chan TK → Liang R, et al. 169  
 Chen S-F → Shen HL, et al. 183  
 Chen G, Pan Q: Potentiation of the antitumor activity of cisplatin in mice by 3-aminobenzamide and nicotinamide 303  
 Child JA → Central Lymphoma Group, et al. 141  
 Colombo N → Gaver RC, et al. 263  
 Conley BA, Egorin MJ, Zuhowski EG, Sinibaldi VJ, Peterson DE: Salivary concentrations of hexamethylene bisacetamide (HMB) in patients receiving 5-day continuous infusions 65  
 Cornell C → Skillen AW, et al. 228  
 Costantini V, Fuschioti P, Allegrucci M, Agnelli G, Nenci GG, Fioretti MC: Platelet-tumor cell interaction: effect of prostacyclin and a synthetic analog on metastasis formation 289  
 Creaven PJ → Pendyala L, et al. 69  
 Crespeigne N → Bleiberg H, et al. 316  
 Csetényi J → Kerpel-Fronius S, et al. 109  
 Cullen MH → Central Lymphoma Group, et al. 141  
 Cusack BJ, Tesnohldek DA, Loseke VL, Vestal RE, Brenner DE, Olson RD: Effect of phenytoin on the pharmacokinetics of doxorubicin in the rabbit 294  
 Dale BM → Reece PA, et al. 348  
 Dalesio O → Bleiberg H, et al. 316  
 Damia G, Zanette ML, Rossi C, Mandelli R, Ferrari A, D'Incalci M: Dose-dependent pharmacokinetics of flavone acetic acid in mice 47  
 Danenberg PV → Link KH, et al. 58  
 Decensi A → Boccardo F, et al. 172  
 Deeb G → Gaver RC, et al. 263  
 de Graeff A, Slebos RJC, Rodenhuis S: Resistance to cisplatin and analogues: mechanisms and potential clinical implications 325  
 de Groot G → Steerenberg PA, et al. 51  
 de Jong WH → Steerenberg PA, et al. 51  
 Dexter DL → Shen HL, et al. 183  
 Dible SE, Siddik ZH, Harrap KR: The comparative tissue distribution of platinum and <sup>14</sup>C in mice receiving <sup>14</sup>C-labelled carboplatin 11  
 D'Incalci M → Damia G, et al. 47  
 D'Incalci M → Zucchetti M, et al. 87  
 Dodion P, Sanders C, Georges P, Kenis Y: In vitro chemosensitivity of brain tumors to cisplatin and its analogues, iproplatin and carboplatin 80  
 Domellöf L → Andersson M, et al. 251  
 Dorr RT, Soble M, Alberts DS: Efficacy of sodium thiosulfate as a local antidote to mechlorethamine skin toxicity in the mouse 299  
 Dowben RM → Gullia KS, et al. 211  
 Dubois J, Atassi G, Hanocq M, Abikhail F: Pharmacokinetics and metabolism of hexamethylmelamine in mice bearing renal cell tumors 282  
 Ducastelle T, Raguenez-Viotte G, Fouin-Fortunet H, Matysiak M, Hemet J, Fillastre JP: The hepatotoxicity of 1-(1-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) in rats. Ultrastructural evidence of a delayed microtubular toxicity 153  
 Egorin MJ → Conley BA, et al. 65  
 Ellis IO → Central Lymphoma Group, et al. 141  
 Erdélyi-Tóth V → Kerpel-Fronius S, et al. 109  
 Evans PC → Paxton JW, et al. 235  
 Ewen C, Perera A, Hendry JH, McAuliffe CA, Sharma H, Fox BW: An autoradiographic study of the intrarenal localisation and retention of cisplatin, iproplatin and paraplatin 241

- Fairchild CR, Maybaum J, Straw JA: Enhanced cytotoxicity with methotrexate in conjunction with hypoxanthine in L1210 cells in culture 26
- Farmen RH → Gaver RC, et al. 263
- Fay JW → Gulliya KS, et al. 211
- Feindel W → Skalski V, et al. 137
- Ferrari A → Damia G, et al. 47
- Fichtinger-Schepman AMJ → Steerenberg PA, et al. 51
- Fillastre JP → Ducastelle T, et al. 153
- Fioretti MC → Costantini V, et al. 289
- Fletcher J → Central Lymphoma Group, et al. 141
- Forbes M → Shen HL, et al. 183
- Forrest G → Gouyette A, et al. 114
- Foster BJ, Grotzinger KR, McKoy WM, Rubinstein LV, Hamilton TC: Modulation of induced resistance of adriamycin in two human breast cancer cell lines with tamoxifen or perhexiline maleate 147
- Fouin-Fortunet H → Ducastelle T, et al. 153
- Fox BW → Ewen C, et al. 241
- Freedman LS, Workman P: When can the infusion period be safely ignored in the estimation of pharmacokinetic parameters of drugs in humans? 95
- Fujiwara Y → Horiuchi N, et al. 246
- Fuschiotti P → Costantini V, et al. 289
- Gaspard MH, Maraninchi D, Stoppa AM, Gastaut JA, Michel G, Toubiana N, Blaise D, Novakovich G, Rossi JF, Weiller PJ, Sainty D, Horschowski N, Carcassonne Y: Intensive chemotherapy with high doses of BCNU, etoposide, cytosine arabinoside, and melphalan (BEAM) followed by autogenous bone marrow transplantation: toxicity and antitumor activity in 26 patients with poor-risk malignancies 256
- Gastaut JA → Gaspard MH, et al. 256
- Gaver RC, Colombo N, Green MD, George AM, Deeb G, Morris AD, Canetta RM, Speyer JL, Farmen RH, Muggia FM: The disposition of carboplatin in ovarian cancer patients 263
- George AM → Gaver RC, et al. 263
- Georges P → Dodion P, et al. 80
- Gerard B → Bleiberg H, et al. 316
- Ghose T → Uadia PO, et al. 175
- Giberti C → Boccardo F, et al. 172
- Giuliani L → Boccardo F, et al. 172
- Gorin NC → Laporte JP, et al. 344
- Gouyette A, Kerr DJ, Kaye SB, Setanoians A, Cassidy J, Bradley C, Forrest G, Soukop M: Flavone acetic acid: a nonlinear pharmacokinetic model 114
- Green MD → Gaver RC, et al. 263
- Green RM → Reece PA, et al. 348
- Grotzinger KR → Foster BJ, et al. 147
- Guarneri D → Boccardo F, et al. 172
- Gulliya KS, Fay JW, Dowben RM, Berkholder S, Matthews JL: Elimination of leukemic cells by laser photodynamic therapy 211
- Gupta S → Vayuvegula B, et al. 163
- Gustavsson B → Andersson M, et al. 251
- Hagen B, Walstad RA, Nilsen OG: Pharmacokinetics of thio-TEPA at two different doses 356
- Häggmark S → Andersson M, et al. 251
- Hamada H → Yusa K, et al. 17
- Hamilton TC → Foster BJ, et al. 147
- Hanocq M → Dubois J, et al. 282
- Hansen SW, Nissen NI, Hansen MM, Hou-Jensen K, Pedersen-Bjergaard J: High activity of mitoxantrone in previously untreated low-grade lymphomas 77
- Hansen MM → Hansen SW, et al. 77
- Hardy JR → Paxton JW, et al. 235
- Harrap KR → Dible SE, et al. 11
- Harris AL → Skillen AW, et al. 228
- Harvey VJ → Paxton JW, et al. 235
- Heinemann V, Murray D, Walters R, Meyn RE, Plunkett W: Mitoxantrone-induced DNA damage in leukemia cells is enhanced by treatment with high-dose arabinosylcytosine 205
- Hemet J → Ducastelle T, et al. 153
- Hendry JH → Ewen C, et al. 241
- Hibasami H, Tsukada T, Maekawa S, Sakurai M, Shirakawa S, Nakashima K: Antitumor effect of methylglyoxal bis(3-aminopropylamino)hydrazones: a new inhibitor of S-adenosylmethionine and ornithine decarboxylases, on human erythroid leukemia K562 cells 187
- Higashihara J, Saito T, Berens ME, Welander CE: Effects of scheduling and ascites-associated macrophages on combined antiproliferative activity of alpha-2b interferon and gamma-interferon in a clonogenic assay 215
- Hill BT, Whelan RDH: Letter to the editors 90
- Hill HS → Reece PA, et al. 348
- Hodson AW → Skillen AW, et al. 228
- Holland JF → Houghton PJ, et al. 201
- Horchowski N → Gaspard MH, et al. 256
- Horiuchi N, Nakagawa K, Sasaki Y, Minato K, Fujiwara Y, Nezu K, Ohe Y, Saijo N: In vitro antitumor activity of mitomycin C derivative (RM-49) and new anticancer antibiotics (FK973) against lung cancer cell lines determined by tetrazolium dye (MTT) assay 246
- Houghton PJ, Tharp R, Houghton JA, Holland JF, Bekesi JG: Evaluation of 3-(p-fluorophenyl)-L-alanyl-3-[m-bis-(2-chloroethyl)aminophenyl]-L-alanyl-L-methionine ethyl ester HCl (PTT.119) against xenografts of human rhabdomyosarcoma 201
- Houghton JA → Houghton PJ, et al. 201
- Hou-Jensen K → Hansen SW, et al. 77
- Howell SB → Chan TCK, et al. 83
- Huben R → Pendyala L, et al. 69
- Inaba M → Ozawa S, et al. 41
- Ishikawa A → Kanamaru R, et al. 197
- Ishioaka C → Kanamaru R, et al. 197
- Isnard F → Laporte JP, et al. 344
- James CA → Philip PA, et al. 321
- Johansson G → Andersson M, et al. 251
- Jones EL → Central Lymphoma Group, et al. 141
- Jongejan HTM, Provoost AP, Molenaar JC: Potentiation of cis-diamminedichloroplatinum nephrotoxicity by amikacin in rats 178
- Kakuta H → Kanamaru R, et al. 197
- Kanamaru R, Konishi Y, Ishioaka C, Kakuta H, Sato T, Ishikawa A, Asamura M, Wakui A: The mechanism of action of quincarmycin citrate (KW 2152) in mouse L1210 cells in vitro 197
- Kanyár B → Kerpel-Fronius S, et al. 104
- Kanyár B → Kerpel-Fronius S, et al. 109
- Kavanagh JA → Central Lymphoma Group, et al. 141
- Kaye SB → Gouyette A, et al. 114
- Kelly KA → Central Lymphoma Group, et al. 141
- Kenis Y → Dodion P, et al. 80
- Kerpel-Fronius S, Verwey J, Stuurman M, Kanyár B, Lelieveld P, Pinedo HM: Pharmacokinetics and toxicity of mitomycin C in rodents, given alone, in combination, or after induction of microsomal drug metabolism 104
- Kerpel-Fronius S, Erdélyi-Tóth V, Somfai-Relle S, Csetényi J, Kovács P, Ujj G, Kanyár B: The role of comparative pharmacokinetics in the planning of human dose escalation: the experience with diacetyldianhydrogalactitol 109
- Kerr DJ → Gouyette A, et al. 114
- Khokhar AR, Wright K, Siddik ZH, Perez-Soler R: Organ distribution and tumor uptake of liposome entrapped cis-bis-neodecanoato Trans-R, R-1,2 diaminocyclohexane platinum (II) administered intravenously and into the proper hepatic artery 223
- Kimura K → Ota K, et al. 333
- Klepp O → Borsi JD, et al. 339
- Konishi Y → Kanamaru R, et al. 197
- Kotasek D → Reece PA, et al. 348
- Kovács P → Kerpel-Fronius S, et al. 109
- Kuoppa K → Nederman T, et al. 21

- Laporte JP, Gorin NC, Lemonnier MP, Isnard F, Najman A: A new combination of two intercalating agents (mitoxantrone + daunomycin) in adult refractory acute leukemia: the DON protocol 344
- Laurent F, Benard P, Canal P, Soula G: Autoradiographic distribution of [ $^{14}$ C]-labelled pimonidazole in rhabdomyosarcoma-bearing rats and pigmented mice 308
- Lawrence HJ → Oster SE 181
- Lelieveld P → Kerpel-Fronius S, et al. 104
- Lemonnier MP → Laporte JP, et al. 344
- Lewis LD → Philip PA, et al. 321
- Liang R, Todd D, Chan TK: HOAP-Bleo as salvage therapy for diffuse aggressive non-Hodgkin's lymphoma 169
- Link KH, Aigner KR, Peschau K, Warthona M, Schwemmler K, Danenberg PV: Concentration and time dependence of the toxicity of fluorinated pyrimidines to HT 29 colorectal carcinoma cells 58
- Litterst CL, Magin R: Alterations in plasma pharmacokinetics of cisplatin in tumor-bearing rats 1
- Loseke VL → Cusack BJ, et al. 294
- Luk GD → Tsai DC 36
- Luna MK → Singh G, et al. 191
- MacLennan ICM → Central Lymphoma Group, et al. 141
- Maekawa S → Hibasami H, et al. 187
- Magin R → Litterst CL 1
- Mandelli R → Damia G, et al. 47
- Maraninchi D → Gaspard MH, et al. 256
- Markman M → Chan TCK, et al. 83
- Martorana G → Boccardo F, et al. 172
- Matthews JL → Gulliya KS, et al. 211
- Matysiak M → Ducastelle T, et al. 153
- Maybaum J → Fairchild CR, et al. 26
- McAuliffe CA → Ewen C, et al. 241
- McDermott B → Pinkerton CR, et al. 271
- McKoy WM → Foster BJ, et al. 147
- McQuillan A → Skalski V, et al. 137
- Meador J → Vayuvegula B, et al. 163
- Mehta A → Pearcey R, et al. 353
- Meyn RE → Heinemann V, et al. 205
- Michel G → Gaspard MH, et al. 256
- Minato K → Horiuchi N, et al. 246
- Mittelman A, Ashikari R, Ahmed T, Savona S, Arnold P, Arlin Z: Phase II trial of fludarabine phosphate (F-Ara-AMP) in patients with advanced breast cancer 63
- Moe PJ → Borsi DJ, et al. 33
- Moe PJ → Borsi JD, et al. 339
- Molenaar JC → Jongejan HTM, et al. 178
- Morris AD → Gaver RC, et al. 263
- Morris RG → Reece PA, et al. 348
- Muggia FM → Gaver RC, et al. 263
- Murray D → Heinemann V, et al. 205
- Najman A → Laporte JP, et al. 344
- Nakagawa S → Horiuchi N, et al. 246
- Nakashima K → Hibasami H, et al. 187
- Nederman T, Carlsson J, Kuoppa K: Penetration of substances into tumor tissue. Model studies using saccharides thymidine and thymidine-5'-triphosphate in cellular spheroids 21
- Nelson JA: A physiological function for multidrug-resistant membrane glycoproteins: a hypothesis regarding the renal organic cation-secretory system 92
- Nenci GG → Costantini V, et al. 289
- Nezu K → Horiuchi N, et al. 246
- Nilsen OG → Hagen B, et al. 356
- Nissen NI → Hansen SW, et al. 77
- Noker PE → Simpson-Herren L, et al. 131
- Novakovich G → Gaspard MH, et al. 256
- O'Brien CJ → Central Lymphoma Group, et al. 141
- Oh Y → Horiuchi N, et al. 246
- Olson RD → Cusack BJ, et al. 294
- Oster SE, Lawrence HJ: Potentiation of anticoagulant effect of coumadin by 5-bromo-2-deoxyuridine (BUDR) 181
- Ota K, Taguchi T, Kimura K: Report on nationwide pooled data and cohort investigation in UFT phase II study 333
- Ozawa S, Yasuda T, Inaba M: Comparison of cellular basis of drug sensitivity of human colon, pancreatic, and renal carcinoma cell lines with that of leukemia cell lines 41
- Pan Q → Chen G 303
- Panasci L → Skalski V, et al. 137
- Paxton JW, Hardy JR, Evans PC, Harvey VJ, Baguley BC: The clinical pharmacokinetics of N-5-dimethyl-9-[(2-methoxy-4-methyl-sulfonylamino)phenylamino]-4-acridinecarboxamide (CI-921) in a phase I trial 235
- Pearcey R, Calvert R, Mehta A: Disposition of ifosfamide in patients receiving ifosfamide infusion therapy for the treatment of cervical carcinoma 353
- Pedersen-Bjergaard J → Hansen SW, et al. 77
- Pendyala L, Creaven PJ, Huben R, Tremblay D, Bertagna C: Pharmacokinetics of Anadron in patients with advanced carcinoma of the prostate 69
- Perera A → Ewen C, et al. 241
- Perez-Soler R → Khokhar AR, et al. 223
- Perren TJ → Central Lymphoma Group, et al. 141
- Peschau K → Link KH, et al. 58
- Peterson DE → Conley BA, et al. 65
- Pfeifle CE → Chan TCK, et al. 83
- Philip T → Pinkerton CR, et al. 271
- Philip PA, Lewis LD, James CA, Rogers HJ: Ifosfamide plasma clearance in relation to polymorphic debrisoquine oxidation 321
- Pinedo HM → Kerpel-Fronius S, et al. 104
- Pinkerton CR, McDermott B, Philip T, Biron P, Ardiet C, Vandenberg H, Brunat-Mentigny M: Continuous vincristine infusion as part of a high dose chemoradiotherapy regimen: drug kinetics and toxicity 271
- Plunkett W → Heinemann V, et al. 205
- Powis G → Brodfuehrer JI, et al. 120
- Powis G → Schlager JJ 126
- Provoost AP → Jongejan HTM, et al. 178
- Raguenez-Viotte G → Ducastelle T, et al. 153
- Reece PA, Hill HS, Green RM, Morris RG, Dale BM, Kotasek D, Sage RE: Renal clearance and protein binding of melphalan in patients with cancer 348
- Reiz S → Andersson M, et al. 251
- Rivas J → Skalski V, et al. 137
- Rodenhuis S → de Graeff A, et al. 325
- Rogers HJ → Philip PA, et al. 321
- Rossi C → Damia G, et al. 47
- Rossi JF → Gaspard MH, et al. 256
- Rozencweig M → Bleiberg H, et al. 316
- Rubinstein LV → Foster BJ, et al. 147
- Sage RE → Reece PA, et al. 348
- Saijo N → Horiuchi N, et al. 246
- Sainty D → Gaspard MH, et al. 256
- Saito T → Higashihara J, et al. 215
- Sakurai M → Hibasami H, et al. 187
- Sanders C → Dodion P, et al. 80
- Sasaki Y → Horiuchi N, et al. 246
- Sato T → Kanamaru R, et al. 197
- Savona S → Mittelman A, et al. 63
- Scheefhals APH → Steerenberg PA, et al. 51
- Schlager JJ, Powis G: Mitomycin C is not metabolized by but is an inhibitor of human kidney NAD(P)H:(quinone-acceptor)oxidoreductase 126
- Schornagel JH → Steerenberg PA, et al. 51
- Schuler D → Borsi DJ, et al. 33
- Schwemmler K → Link KH, et al. 58

- Sessa C → Zucchetti M, et al. 87  
 Setanoians A → Gouyette A, et al. 114  
 Sharma H → Ewen C, et al. 241  
 Shen HL, Chen S-F, Behrens DL, Whitney CC, Dexter DL, Forbes M: Distribution of the novel anticancer drug candidate Brequinar Sodium (DuP 785, NSC 368390) into normal and tumor tissues of nude mice bearing human colon carcinoma xenografts 183  
 Shirakawa S → Hibasami H, et al. 187  
 Siddik ZH → Dible SE, et al. 11  
 Siddik ZH → Khokhar AR, et al. 223  
 Simmons AV → Central Lymphoma Group, et al. 141  
 Simpson-Herren L, Noker PE, Wagoner SD: Variability of tumor response to chemotherapy. II. Contribution of tumor heterogeneity 131  
 Singh G, Luna MK, Ardalan B: Studies on the mechanism of 2-deazaguanine cytotoxicity in L1210-sensitive and -resistant cell lines 191  
 Sinibaldi VJ → Conley BA, et al. 65  
 Skalski V, Rivas J, Panasci L, McQuillan A, Feindel W: The cytotoxicity of sarcosinamide chloroethylnitrosourea (SarCNU) and BCNU in primary gliomas and glioma cell lines: analysis of data in reference to theoretical peak plasma concentrations in man 137  
 Skillen AW, Buamah PK, Cantwell BMJ, Cornell C, Hodson AW, Harris AL: Urinary protein and enzyme excretion in patients receiving chemotherapy with the *cis*-platinum analogs carboplatin (CBDCA, JM8) and iproplatin (CHIP, JM9) 228  
 Slater L → Vayuvegula B, et al. 163  
 Siebos RJC → de Graeff A, et al. 325  
 Soble M → Dorr RT, et al. 299  
 Somfai-Relle S → Kerpel-Fronius S, et al. 109  
 Soukop M → Gouyette A, et al. 114  
 Soula G → Laurent F, et al. 308  
 Speyer JL → Gaver RC, et al. 263  
 Steerenberg PA, Vendrik CPJ, de Jong WH, de Groot G, Fichtinger-Schepman AMJ, Scheeffhals APH, Schornagel JH: Resistance and cross-resistance of the IgM immunocytoma in the LOU/M Wsl rat for cisplatin, carboplatin, and iproplatin 51  
 Stoppa AM → Gaspard MH, et al. 256  
 Straw JA → Fairchild CR, et al. 26  
 Stuart NSA → Central Lymphoma Group, et al. 141  
 Stuurman M → Kerpel-Fronius S, et al. 104  
 Taetle R → Chan TCK, et al. 83  
 Taguchi T → Ota K, et al. 333  
 Tesnohldek DA → Cusack BJ, et al. 294  
 Tharp R → Houghton PJ, et al. 201  
 Todd D → Liang R, et al. 169  
 Tremblay D → Pendyala L, et al. 69  
 Tsai DC, Luk GD: The growth-inhibitory effect of 4-hydroperoxycyclophosphamide against human non-small cell lung carcinoma is enhanced by low-dose difluoromethylornithine 36  
 Tsukada T → Hibasami H, et al. 187  
 Tsuruo T → Yusa K, et al. 17  
 Tubiana N → Gaspard MH, et al. 256  
 Uadia PO, Blair AH, Ghose T: Hydrolysis of methotrexate-immunoglobulin conjugates by liver homogenates and characterization of catabolites 175  
 Ujj G → Kerpel-Fronius S, et al. 109  
 Vandenberg H → Pinkerton CR, et al. 271  
 Vayuvegula B, Slater L, Meador J, Gupta S: Correction of altered plasma membrane potentials. A possible mechanism of cyclosporin A and verapamil reversal of pleiotropic drug resistance in neoplasia 163  
 Vendrik CPJ → Steerenberg PA, et al. 51  
 Verwey J → Kerpel-Fronius S, et al. 104  
 Vestal RE → Cusack BJ, et al. 294  
 Wagoner SD → Simpson-Herren L, et al. 131  
 Wakui A → Kanamaru R, et al. 197  
 Walstad RA → Hagen B, et al. 356  
 Walters R → Heinemann V, et al. 205  
 Walton MI, Workman P: Pharmacokinetics and metabolism of the mixed-function hypoxic cell sensitizer prototype RSU 1069 in mice 275  
 Warthorn M → Link KH, et al. 58  
 Weiller PJ → Gaspard MH, et al. 256  
 Welander CE → Higashihara J, et al. 215  
 Whelan RDH → Hill BT 90  
 Whitney CC → Shen HL, et al. 183  
 Wientjes MG, → Au JL-S, et al. 5  
 Wilke TJ → Brodfuehrer JI, et al. 120  
 Willems Y → Zucchetti M, et al. 87  
 Workman P → Freedman LS 95  
 Workman P → Walton MI 275  
 Wright K → Khokhar AR, et al. 223  
 Yasuda T → Ozawa S, et al. 41  
 Yusa K, Hamada H, Tsuruo T: Comparison of glutathione S-transferase activity between drug-resistant and -sensitive human tumor cells: Is glutathione S-transferase associated with multi-drug resistance? 17  
 Zanette ML → Damia G, et al. 47  
 Zucchetti M, D'Incalci M, Willems Y, Cavalli F, Sessa C: Lack of effect of cisplatin on i.v. L-PAM plasma pharmacokinetics in ovarian cancer patients 87  
 Zuhowski EG → Conley BA, et al. 65

## Subject index of volume 22

- ADPRT inhibitors 303  
 Adriamycin 17, 90  
 Adriamycin resistance 147  
 Advanced breast cancer 63  
 Advanced carcinoma of the prostate 69  
 Alizapride 316  
 Alkylating agents 299  
 Amikacin 178  
 Analogues 325  
 Analogues 80  
 Anandron 69  
 Antiemetic agent 316  
 Antitumor agent 120  
 Antitumor effect 187  
 Arabinosylcytosine 205  
 Ascites-associated macrophages 215  
 Autoradiography 241, 308
- BCNU 137  
 Biochemical modulation 333  
 Bone marrow levels 83  
 Bone marrow transplantation 256  
 Brain tumours 80  
 Breast cancer 147  
 Brequinar sodium DuP 785 183  
 BUDR 181
- Carboplatin 11, 51, 80, 228, 241, 263  
 Cardiotoxicity 294  
 Catabolites 175  
 CCNU 153  
 Cell lines 147  
 Cellular drug sensitivity 41  
 Cervical carcinoma 353  
 Chemosensitivity 80  
 Chemotherapy 131, 316  
 CHIP 228  
 Chloroethylnitrosourea 137  
 CI-921 235  
 Cisplatin 1, 51, 80, 87, 241, 303, 316, 325  
 Clonogenic assay 215  
 Colorectal carcinoma 58  
 Combination chemotherapy 141, 344  
 Comparative pharmacokinetics 104  
 Coumadin 181  
 Cyclosporin A 163  
 Cytotoxicity 26, 90, 137, 191
- Daunomycin 344  
 3-Deazaguanine 191  
 Debrisoquine 321  
*cis*-Diamminedichloroplatinum 178  
 Difluoromethylornithine 36  
 DNA damage 205  
 Dose escalation 109  
 Doxorubicin metabolism 294  
 Doxorubicinol metabolism 294  
 Drug kinetics 271  
 Drug metabolism 104  
 Drug resistance 325
- Estracyt 172
- FK973 246  
 Flavone acetic acid 47, 114  
 Fludarabine 63
- Fluoropyrimidines 58  
 5-Fluorouracil 251  
 5'-deoxy-5-Fluorouridine 5  
 Futraful 333
- GFA 179  
 Glycoproteins 92  
 GST-activity 17
- Hemodynamics 251  
 Hepatic artery 223  
 Hepatotoxicity 153  
 Hexamethylene bisacetamide 65  
 Hexamethylmelamine 282  
 High-dose chemoradiotherapy 271  
 High-dose chemotherapy 256  
 High-grade lymphoma 141  
 Human colon cancer 41, 183  
 Human leukemia 41  
 Human leukemia cells 187  
 Hydrolysis 175  
 Hypoxic cell 308  
 Hypoxic cell sensitizer 275
- Ifosfamide 321, 353  
 IgM 51  
 Immunocytoma 51  
 Infusion period 95  
 Intercalating agents 344  
 $\alpha$ -2b-Interferon 215  
 $\gamma$ -Interferon 215  
 Iproplatin 51, 80, 228, 241
- Kidney 126
- L1210 191  
 Laser photodynamic therapy 211  
 L1210 cells 26  
 Leukemia 344  
 Leukemic cells 211  
 Liposome 223  
 L-PAM 87  
 Lymphomas 256
- Melphalan 348  
 Membrane potentials 163  
 Metastases 289  
 Methotrexate 33, 326, 339  
 Methotrexate-hypoxanthine combination 26  
 Methotrexate immunoglobuline conjugates 175  
 Methylglyoxal bis(3-aminopropylamido)hydrazide 187  
 Mitomycin C 104, 126  
 Mitoxantrone 77, 205, 344  
 MTT assay 246  
 Multidrug resistance 92
- Neoplasms 172  
 Nephrotoxicity 178  
 Non-Hodgkin's lymphoma 77, 141, 169
- Organ distribution 223  
 Ornithine decarboxylase 187  
 Ovarian cancer 87, 263, 356
- Penetration 21  
 Pharmacokinetic parameters 95



- Pharmacokinetics 1, 33, 47, 69, 83, 87, 104, 120,  
235, 251, 275, 282, 356  
Pharmacokinetic model 114  
Pharmacokinetic parameters 339  
Phase II study 141  
Phase I trial 109  
Phenytoin 294  
Plasma, clearance 321  
Plasma uridine clearance 83  
*cis*-Platinum analogs 223, 228  
Pleiotropic drug resistance 163  
Poor risk malignancies 256  
Prostaglandins 289  
Prostate cancer 172  
Protein binding 348  
PTT.119 201
- Quinocarmycin citrate (KW 2152) 197  
Quinone reductase 126
- Reduced toxicity 303  
Renal cell tumors 289  
Renal clearance 348  
Rhabdomyosarcoma 201, 308  
RM-49 246  
RSU 1069 275
- Saccharides 21  
Salvage therapy 169  
Skin toxicity 299  
Small cell lung carcinoma 36  
Spheroids 21  
Sulfamic acid diester 120  
Synergistic antitumor 303
- Tamoxifen 147  
Thiols 299  
Thiosulfate 299  
Thio-TEPA 356  
Thymidine 21  
Tissue distribution 11, 183  
Toxicity 58, 104, 256, 271  
Tumor heterogeneity 131  
Tumor response 131  
Tumor tissue 21
- UFT 333  
Uracil 333  
Uridine 5  
Urinary protein 228
- Vinblastine 17  
Vincristine 17, 271
- Xenografts 201

